Clarus Therapeutics Holdings, Inc. (CRXTQ)
Clarus Therapeutics Holdings, Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Northbrook, IL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $72,829. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -404.9%. Its beta of 1.68 implies it has historically moved more than the broad market.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
Clarus Therapeutics Holdings, Inc. is most often compared with the following Healthcare names: